SEC Form 4 · accession 0001171843-17-004000
Sucampo Pharmaceuticals, Inc. · SCMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Maxwell Donley
Officer — EVP, Global HR, IT & Strategy
Period of report
Jun 30, 2017
Accepted (ET)
Jul 7, 2017 · 4:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001365216
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, Class A (ESPP)F1,F2 | Jun 30, 2017 | A | 336 | $8.93 | A | 2,668 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period April 1, 2017 through June 30, 2017. This transaction is exempt under Rule 16(b)-3(c).
- F2In accordance with the ESPP, these shares were purchased at 85% of the June 30, 2017 closing price of the issuer's common stock.